N. fowleri is remarkably sensitive to one such inhibitor, HEX, with EC50 values about 6-fold lower than those required to kill ENO-1-deficient GBM cells, the cancer type that was the target of the initial phosphonate design campaign [5]. This evidence concerns the gene HHEX and glioblastoma.